Caribou Biosciences

Caribou Biosciences is a leading biotechnology company in genome engineering. We develop technology-based solutions for cellular engineering and analysis based on the CRISPR-Cas9 technology platform. Cas9, when paired with a guide RNA, cuts double-stranded DNA allowing for specific changes to DNA. These site-specific DNA modifications can be utilized to carry out sophisticated gene knock-outs or knock-ins. Caribou's technologies mark a revolutionary development that allows scientists to engineer nearly any part of any genome with extreme flexibility. Forbes Magazine has called Cas9 the protein that "could change biotech forever" and the New York Times has noted that "the pace of new discoveries and applications is dizzying." Caribou's tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology.

Company Growth (employees)
Berkeley, US
Size (employees)
51 (est)
Caribou Biosciences was founded in 2011 and is headquartered in Berkeley, US

Key People at Caribou Biosciences

Rachel E. Haurwitz

Rachel E. Haurwitz


Caribou Biosciences Office Locations

Caribou Biosciences has an office in Berkeley
Berkeley, US (HQ)
2929 7th St

Caribou Biosciences Data and Metrics

Summary Metrics

Founding Date


Total Funding

$44.5 m

Latest funding size

$30 m

Time since last funding

over 1 year


Caribou Biosciences's latest funding round in May 2016 was reported to be $30 m. In total, Caribou Biosciences has raised $44.5 m

Traffic Overview of Caribou Biosciences

Caribou Biosciences Online and Social Media Presence

Caribou Biosciences News and Updates

China sides with Emmanulle Charpentier and Jennifer Doudna in CRISPR patent war

 Continuing the patent dispute internationally, China has now given the Charpentier/Doudna side a patent to edit genes in the country. CRISPR pioneers Emmanuelle Charpentier and Jennifer Doudna lost a patent case to the Broad Insititute earlier this year when the court determined the Broad Insititut…

Caribou Bioscience’s Rachel Haurwitz will chat with us about clipping out cancer at Disrupt NY

 CRISPR Cas9 — the framework to program and edit our genetic code — has been hailed as the technological discovery of the century. The Cas9 enzyme acts as a type of genetic scissors, allowing scientists to snip out, edit and replace DNA at certain intervals along the genome and it holds great promis…

Only 3 more days to save on Disrupt NY tickets

 Alright future Disrupt attendees. We gave you an extra week to save $1,000 on Disrupt NY 2017 tickets, but this week we aren’t feeling so generous. You now have just three days left to get an early-bird ticket for $1,995 before prices jump to $2,995 after Friday. Seriously, no more extensions. This…

Synthetic Biology Game Changers: Startups Redesigning Biological Products

Missed our Innovation Summit? Sign up here and see what you missed. While a number of startups tend to focus on achieving “product-market fit” and innovating around industry norms, there are plenty of companies looking to disrupt the world with … Continued

Caribou Biosciences Company Life and Culture

You may also be interested in